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Abstract
Objective To assess medical teams’ ability to recognize
adverse drug events (ADEs) in older inpatients.
Methods The study cohort comprised 250 patients aged
65 years or older consecutively admitted to Internal Medi-
cine wards of three hospitals in the Netherlands between
April and November 2007. An independent expert team
identified ADEs present upon admission or occurring during
hospitalization by a structured retrospective patient chart
review. For all ADEs identified, the expert team assessed
causality, severity, preventability, and recognition by medi-
cal teams.
Results The medical teams did not recognize 19.9 % of all
ADEs present upon admission {60.4 ADEs [95 % confi-
dence interval (CI) 51.5–70.8] per 100 hospitalizations}
and 20.3 % of all ADEs occurring during the hospital stay
[47.2 ADEs (95 % CI 39.4–56.5) per 100 hospitalizations].
Unrecognized ADEs were significantly more often ADEs
with possible causality (p00.014, df01), ADEs caused by
medication errors (p<0.001, df01), and ADEs not manifest-
ing as new symptoms (p<0.001, df01). The medical teams
did not recognize 23.2 % of mild to moderately severe ADEs
and 16.5 % of severe, life-threatening, or fatal ADEs. The
recognition of ADEs varied with event type.
Conclusions The recognition of ADEs by medical teams
was substantial for those ADEs with evident causality and
with clinically apparent and severe consequences. ADEs
mimicking underlying pathologies with a lower severity
went unrecognized much more often, as did those resulting
only in abnormal laboratory values. Tools to improve the
recognition of ADEs by medical teams should, therefore,
focus on those ADEs that are more challenging to detect.
Keywords Adverse drug events . Medication safety .
Elderly . Hospital
Introduction
Adverse Drug Events (ADEs) are the most frequent type of
adverse events in medical inpatients [1] and are associated
with a prolonged hospital stay, a twofold increase in the risk
of death, and higher costs [2]. Approximately 50 % of ADEs
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are preventable [3]. Awidely accepted definition of an ADE
is any harm occurring during drug therapy which may result
from either appropriate care (non-preventable ADE) or from
suboptimal care (preventable ADE) (i.e., a medication error)
[4].
It is widely acknowledged that older patients are espe-
cially at risk for ADEs [5, 6], primarily due to multiple co-
morbidities, polypharmacy, and higher vulnerability due to
decreased organ function, increased susceptibility to drugs,
and frequently present cognitive impairment [7, 8]. Further-
more, correct and timely diagnosis is often hampered by
atypical disease presentation, such as falls or delirium [5, 9].
Therefore, not only avoiding ADEs in older inpatients, but
also, when they do occur, timely recognition of ADEs may
pose a significant challenge for medical teams [9, 10].
Failure to recognize ADEs during the hospital stay may lead
to inappropriate actions causing even more harm [10]. The
study by Nebeker et al. [11] reports that in a general inpa-
tient population, 24 % of ADEs subsequently identified by
the researchers were not recognized by the medical teams.
Although the body of literature on the occurrence of
(preventable) ADEs in older hospitalized patients is exten-
sive [5, 12–22], data on medical teams’ ability to timely
recognize ADEs in this vulnerable patient population are
limited to the Emergency Department setting [23].
Therefore, we conducted a multicenter cohort study with
the aim to gain a detailed insight into recognition of ADEs
by medical teams in older inpatients. In order to do so, both
ADEs present upon admission and those occurring during
the hospital stay were included in our analysis.
Material and methods
Study setting
The study was performed in the Internal Medicine wards of
three teaching hospitals in the Netherlands: the Academic
Medical Center (AMC) in Amsterdam, a 1,002-bed academ-
ic hospital, the Westfriesgasthuis (WFG) in Hoorn, a 506-
bed regional teaching hospital, and the Spaarne Hospital
(SH) in Hoofddorp, a 520-bed tertiary teaching hospital.
The Internal Medicine wards were staffed by teams consist-
ing of attending physicians, junior and senior residents, and
interns on rotation, caring together for an average of ten
adult patients daily. All three Hospital Pharmacy Depart-
ments offered only off-ward, daily clinical services, includ-
ing preparation of parenteral medications by pharmacy
technicians, on-call availability of a hospital pharmacist for
pharmacotherapeutic or toxicological consultations, and
therapeutic drug monitoring (TDM). In addition, Comput-
erized Physician Order Entry (CPOE) systems with limited
clinical decision support were in place in all three
participating hospitals. These clinical decision support sys-
tems (CDSSs) generated three types of alerts based only on
the prescribing data: drug–drug interactions, drug–drug
duplications, and overdoses. No other sources, such as lab-
oratory values or diagnostic tests results, were linked to
these operating CDSSs.
Study design
Data presented in this study are baseline results of an inter-
rupted time-series study on the effects of the Ward-oriented
pharmacy In Newly admitted Geriatric Seniors (WINGS)
study [24]. Over a period of 8 months (April–November
2007), 250 patients aged 65 years or older were included in
the study during three sampling periods: 90, 80, and 80
consecutively admitted patients were enrolled during the
first (April–May 2007), second (July–August 2007) and
third (October–November 2007) sampling period,
respectively.
The WINGS study was conducted within the framework
of the CAREFUL (pharmacist Coordinated ADE Reducing
Efforts For Use in all Levels of healthcare) research program
based on a cooperative effort between Leiden University
Medical Center, AMC Amsterdam, University Medical
Center Groningen, and University Medical Center Utrecht/
Utrecht University.
Patients
All patients aged 65 years or older who were taking five or
more medications on the day of admission and who were
admitted to an Internal Medicine ward of the participating
hospitals during one of the three sampling periods were
eligible for enrolment in the study. Patients were excluded
if they were scheduled for chemotherapy, radiation therapy,
or stem cell/kidney transplantation, were discharged within
24 h, and/or had been transferred from other hospitals or
other non-medical wards within the study hospitals. Only
the first hospitalization during the baseline period per each
included patient was reviewed (index hospitalization). The
index hospitalization included the day of admission and all
days of the subsequent hospitalization until the patient was
discharged home, transferred to a non-medical ward within
the same hospital, or transferred to another healthcare facil-
ity (e.g., hospital, nursing home).
Measurement and classification of ADEs
No golden standard currently exists for the measurement,
definition, and assessment of ADEs [25, 26]. The definitions
used in this study, as well as the method and assessment of
ADEs follow recommendations by experts and are also
widely accepted [4, 26–28]. An ADE was classified as any
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harmful event occurring during drug therapy that resulted
either from appropriate care (non-preventable ADEs) or
from medication errors (preventable ADE) [4]. Both errors
of omission or commission were included in this study.
Harmful events were defined as either abnormal laboratory
values or clinical symptoms. ADEs were included if they
resulted in an outbreak of new symptoms/pathology, in
worsening of existing or new symptoms/pathology, or in a
delay or lack of any expected improvement of existing or
new symptoms/pathology [4].
A detailed description of the method applied in this study
can be found elsewhere [24]. In summary, after an included
patient was discharged or transferred, trained research
nurses and pharmacy students first gathered all information
available on the index hospitalization (medical and nurse
patients’ files, medication charts, discharge letters and other
medical correspondence, laboratory and diagnostic results)
and completed a case report form (CRF) in which ‘so-
called’ triggers were incorporated. These triggers were
adapted from the Institute of Healthcare Improvement
(IHI) ADE trigger-tool [29]. Examples of IHI ADE triggers
are the ordering of vitamin K which may be related to
overanticoagulation with coumarines, or a digoxin level of
>2.0 μg/L which may be related to digoxin toxicity. These
triggers were ticked off by the researchers when applicable,
with an aim to prompt expert team attention to specific
events which may potentially be ADEs [30]. Second, the
information collected on the index hospitalization together
with the CRFs were presented to two independent experts,
namely, a senior specialist in Internal Medicine (LA) and a
senior clinical pharmacist specializing in geriatric medicine
(CS), both of whom were experienced in systematic ADE
identification. These two experts reviewed all data indepen-
dently and subsequently discussed their findings during
scheduled meetings. A structured ADE assessment was used
to determine the causality between a drug and an adverse
event, preventability and severity of an ADE, recognition of
ADEs by medical teams, and, when applicable, type of
underlying medication error. Only ADEs with a causality
score of nearly certain, probable, and possible, as assessed
according to the World Health Organization–Uppsala Med-
ical Centre (WHO-UMC) criteria were included [31]. ADEs
caused by a medication error were classified as preventable.
The severity of an ADE was scored according to Common
Terminology Criteria for Adverse Events ver. 3.0
(CTCAEv3) developed by the U.S. National Cancer Insti-
tute [32]. For example, for hyperkalemia, severity of the
ADE is classified as mild if the potassium concentration is
higher than the upper limit of normal (5.5 mmol/L), as
moderate if higher than 5.5–6.0 mmol/L, as severe if higher
than 6.0–7.0 mmol/L, and as life-threatening if >7.0 mmol/
L. Medication errors were classified according to the Dutch
Central Medication Incidents Registration [33] and defined
as errors in drug prescribing, transcribing, processing, com-
pounding, stocking, dispensing, administering, or monitor-
ing [33]. To assess if an medication error occurred, we
utilized prevailing national [34] and local pharmacothera-
peutic guidelines, as well as all alerts generated by the
CDSSs operating in the participating hospitals.
The expert team assessed an ADE as unrecognized if,
based on the patient charts reviewed, no indication was
found that a medical team involved recognized patient harm
as being medication related and/or no certain documented
actions were targeted at that specific ADE.
During the scheduled meetings, the experts reached con-
sensus on all aspects of the ADE assessment for an ADE to
be included.
Main outcome measures
The main outcome measures were: (1) rate of ADEs present
upon admission and (2) rate of ADEs occurring during the
hospital stay. Both outcomes were expressed as rates per
100 hospitalizations.
Statistical methods
Descriptive statistics were applied for the analysis of patient
characteristics, including means, standard deviations (SD),
medians, and percentiles. To test for differences between
patients included in the three hospitals, normally distributed
continuous variables were compared using a one-way anal-
ysis of variance test and categorical variables were analyzed
by using the chi-square test. Non-normally distributed con-
tinuous variables were compared using the Kruskall–Wallis
test.
To compare the distributions of ADE severity, causality,
type of harm manifestation, and type of events between
unrecognized and recognized ADEs, we used the chi-
square test or Fisher’s exact test.
Multivariable backward logistic regression analyses were
conducted to determine which patient factors were indepen-
dently associated with no recognition of ADEs present upon
admission and which factors led to no recognition of ADEs
occurring during hospitalization. Variables in the model for
no recognition of ADEs present upon admission included
age, sex, number of preadmission medications, the type of
admission (elective or acute), the presence of cognitive
impairment on admission (yes/no), and the Charlson
Comorbidity Index score [35]. Variables in the model for
no recognition of ADEs occurring during the hospital stay
included age, sex, number of hospital medications, length of
stay on an Internal Medicine ward, the presence of cognitive
impairment on admission (yes/no), and the Charlson
Comorbidity Index score [35]. A p value of<0.05 was
considered to be statistically significant. Computer software
Eur J Clin Pharmacol (2013) 69:75–85 77
SPSS ver. 18.0 (SPSS, Chicago, IL) was used for the
calculations.
Ethical considerations
The WINGS study protocol [24] was presented to The
Medical Ethics Committee of the University of Amsterdam.
The Medical Ethics Committee discussed the protocol and
exempted it from review and official approval. According to
the Dutch Medical Research Involving Human Subjects
Act, such a review and approval were not required because
the study did not involve direct interaction with human
subjects. This research used retrospective patient chart re-
view to assess the extent of suboptimal care related to
ADEs. Therefore, the integrity of patients was not influ-
enced, and all patient data were analyzed anonymously by




Demographic characteristics of the 250 patients included in
the study are shown in Table 1. The three groups of patients
in the participating hospitals only differed in the median
length of hospital stay on an Internal Medicine ward (medi-
an, with 25th and 75th percentile: AMC, 5.6 days (3.6,
7.9 days); WFG, 5.9 days (2.8, 8.1 days); SH, 7.4 days
(4.8, 11.8 days); p00.025). Therefore, patients’ character-
istics are in Table 1 presented after pooling.
Main outcomes
A total of 269 ADEs in 164 patients were identified. We
found 60.4 ADEs (95 % CI 51.5–70.8) present upon
admission per 100 hospitalizations (151 ADEs), of which
19.9 % (30/151) remained unrecognized during the sub-
sequent hospitalization. During the hospital stay, we
found 47.2 ADEs (95 % CI 39.4–56.5) per 100 hospital-
izations (118 ADEs) to have occurred, of which 20.3 %
(24/118) remained unrecognized (Table 2). When only
severe, life-threatening, or fatal ADEs were considered,
the overall proportion of unrecognized ADEs decreased
from 20.1 to 7.8 %. When only ADEs assessed as
having nearly certain or probable event–drug causality
were considered, the overall proportion of unrecognized
ADEs decreased from 20.1 to 15.2 %.
The expert team assessed 135 ADEs as preventable
(50.2 %), i.e., caused by medication errors, of which the
medical teams did not recognize 30.4 %. Medication errors
most often identified were: omissions in prescribing (25.2 %),
prescribing of too high or too low doses (25.2 %), prescribing
of medication while contra-indicated (20.0 %), wrong phar-
macotherapy choice for a known indication (excluding eco-
nomic considerations) (11.1 %), drug–drug interactions
(combinations should have been avoided or dosages adjusted)
(7.4 %), drug administration errors (5.9 %), and lack of TDM
(5.2 %).
Table 1 Patient characteristics
Characteristic Total (n0250)
Age, years (mean ± SD) 76.9±7.5
Female, n (%) 133 (53.2)
Living independent, n (%) 211 (84.4)
Acute admission, n (%) 213 (85.2)
Length of stay, days, median (25th, 75th percentile) 5.9 (3.6, 9.6)
Specialty of wards, n (%)
General internal medicine 98 (39.2)
Gastroenterology 51 (20.4)
Nephrology 46 (18.4)
Oncology and hematology 37 (14.8)
Rheumatology 18 (7.2)
Number of preadmission medications (mean ± SD) 7.3±3.2
Number of hospital medications (mean ± SD) 11.0±4.1
Number of concomitant diseases (mean ± SD) 3.16±1.7
Most frequent types of diseases, n (%)
Cardiovascular 179 (71.6)
Malignancy 94 (37.6)
Diabetes mellitus 84 (33.6)






Charlson Comorbidity Index score, n (%)
0 points 24 (9.6)
1–2 points 108 (43.2)
3–4 points 63 (25.2)
≥5 points 55 (22.0)






SD, Standard deviation; MDRD study, Modification of Diet in Renal
Disease study; eGFR, estimated glomerular filtration rate
a Length of stay on the Internal Medicine wards
b For 10 patients no laboratory tests were run during the hospital stay to
assess renal function
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The intra-rater agreement of the involved expert team
(initial vs. second review by LA and CS 1 year later) was
substantial for presence of an ADE (κ00.74), preventability
of ADEs (κ00.68), and severity (κ00.93).
Characteristics of recognized and unrecognized ADEs
A substantial number of ADEs identified by the expert team
caused serious patient harm (47.2 %; 127/269 ADEs were
scored as severe, life-threatening, or fatal). Of these ADEs
16.5 % were not recognized by the medical teams (Table 2).
We identified four fatal ADEs (all recognized by the medical
teams) and 38 ADEs which caused life-threatening patient
harm [5 (15.2 %) unrecognized by the medical teams].
Differences in distributions between the unrecognized and
recognized ADEs were found for causality (p00.014, df01),
preventability (p<0.001, df01), and type of harm due to an
ADE (p<0.001, df01). In comparison with recognized
ADEs, unrecognized ADEs were more often ADEs with a
possible drug–event causality score, preventable ADEs, and
less often ADEs which resulted in new symptoms or pathol-
ogy. The most frequent events related to ADEs (87.0 % of
all ADEs identified), their severity and causality, and
recognition are shown in Table 3, as well as medica-
tions most frequently involved in those ADEs listed per
event type.
All ADEs resulting in hemorrhage, raised International
Normalization Ratio (INR), skin reaction, and, except for
one event per category, all ADEs resulting in constipation or
ileus, and hyper- and hypoglycemia were recognized by the
medical teams involved (Table 3). Causality of those events
with medication was assessed as nearly certain or probable
for 64.3 % of the ADEs resulting in raised INR to 100.0 %
of the skin reaction ADEs and ADEs resulting in constipa-
tion/ileus. More than half of ADEs resulting in hemorrhage
(56.5 %) and hyper-hypoglycemia (66.7 %), and all ADEs
resulting in raised INR (100.0 %) were severe or worse
according to the CTCAEv3 criteria [32],
The proportions of unrecognized ADEs were higher
for events in the following categories: central nervous
system (CNS), (23.8 % unrecognized), hypotension/bra-
dycardia (27.8 % unrecognized), anemia (40.0 % unrec-
ognized), nausea and vomiting (44.4 % unrecognized),
raised creatinine/renal insufficiency (47.1 % unrecog-
nized), and raised liver transaminases (LTs)/liver insuffi-
ciency (53.3 % unrecognized) (Table 3). Of the latter two
categories, 75.5 % manifested as an abnormal laboratory
test result only. The majority of these ADEs was
assessed as having nearly certain or probable drug cau-
sality (66.7 % for CNS events to 94.4 % for hypoten-
sion/bradycardia). The proportions of severe or worse
ADEs according to CTCAEv3 criteria [32] were, except
for CNS events, lower (26.7 % for anemia to 44.4 % for
hypotension/bradycardia) than those for ADEs which
were (almost) all recognized. Of the CNS events,
66.7 % was scored as severe or worse.





p value and degrees
of freedom
Time of identification
ADE present upon admission 30 (55.6) 121 (56,3) 0.924; df01
ADE occurred during the hospital stay 24 (44.4) 94 (43,7)
Severity
Mild to moderate 33 (61.1) 109 (49.3) 0.171; df01
Severe or worse (life-threatening or fatal) 21 (38.9) 106 (50.7)
Causality
Nearly certain or probable/likely 41 (75.9) 191 (88.8) 0.014; df01
Possible 13 (24.1) 24 (11.2)
Preventability
Non-preventable 13 (24.1) 121 (56.3) <0.001; df01
Preventable 41 (75.9) 94 (43.7)
Type of events
Clinical symptom 27 (50.0) 135 (62.8) 0.086; df01
Laboratory abnormality 27 (50.0) 80 (37.2)
Type of harm manifestation
New harm 9 (16.7) 174 (80.9) <0.001; df01
Sustained/worsened harm or delayed recovery from harm 45 (83.3) 41 (19.1)
ADE, Adverse drug event; df, degrees of freedom
Data are presented as the number of patients, with the percentage given in parenthesis
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Multivariable analyses
The Charlson Comorbidity Index score [32] was the only
characteristic independently associated with no recognition
of ADEs present upon admission [odds ratio (OR) 0.76,
95 % CI, 0.59–0.97; p00.026). Patients with cognitive
impairment on admission seemed to have a higher risk for
unrecognized ADEs being present upon admission in com-
parison to patients without cognitive impairment (OR 2.4,
95 % CI 1.00–5.85; p00.05). No independently associated
patient characteristics were found for having an unrecog-
nized ADE occurring during the hospital stay.
Discussion
Our study focused on medical teams’ ability to recognize
ADEs in hospitalized older patients aged 65 years or older
and included an assessment of both ADEs present upon
admission and ADEs occurring during the hospital stay.
We found that of all 269 ADEs identified by our expert
team, 20 % remained unrecognized by medical teams during
the hospital stay. Of the unrecognized ADEs, more than a
half (56 %) were ADEs present upon admission, and the
majority (76 %) were ADEs caused by medication errors.
Our results show that patients’ characteristics as well as
ADE characteristics impact the ability of medical teams to
recognize ADEs in older inpatients.
The rates of both ADEs present upon admission (60.4 per
100 hospitalizations) and ADEs occurring during the hospital
stay (47.2 per 100 hospitalizations) identified in this study are
markedly higher than those reported in previous ADE studies
in older patients [5, 12–22]. These differences can partly be
explained by differences in the type of identification method
used, the clinical setting, and in the definitions of the out-
comes applied [25, 36, 37]. In this study, we used a definition
of an ADE which included not only new ADEs, but also
worsened and sustained harm or delayed recovery from harm
due to both preventable and non-preventable ADEs [4, 24].
Furthermore, by utilizing an adapted IHI ADE trigger-tool
[29] as an aid, our chart review was more structured and
may, therefore, be more accurate [27, 30, 38]. We also
deployed a physician–pharmacist team to review patient
charts because the professional knowledge of this
Table 3 Most frequently identified ADEs and their recognition by the medical teams during the hospital stay
Type of events
(examples of most often involved medication)
No. of all events identified by the
expert team (% unrecognized)
No. of severe or worse
events (% unrecognized)
No. of nearly certain
and probable events
(% unrecognized)
Electrolyte disturbances (diuretics/RAAS inhibitors) 43 (18.6) 11 (27.3) 34 (17.6)
Hemorrhage (coumarines/anti-platelet medication,
omissions of gastro-protective medication)
23 (0.0) 13 (0.0) 19 (0.0)
Central nervous system eventsa
(opiates/benzodiazepines/beta-blockers)
21 (23.8) 14 (21.4) 14 (7.1)
Hypotension/bradycardia
(beta-blockers/diuretics/digoxin)
18 (27.8) 8 (12.5) 17 (29.4)
Delayed recovery from an infection or
sustained infectionsb (antibiotics)
18 (11.1) 15 (13.3) 16 (6.3)
Raised creatinine/renal insufficiency
(antibiotics/NSAIDs/RAAS inhibitors/diuretics)
17 (47.1) 6 (33.3) 15 (53.3)
Constipation or ileus
(omission of laxatives while taking opiates)
16 (6.3) 6 (0.0) 16 (6.3)
Hyper- and hypoglycemia
(anti-diabetic drugs/corticosteroids)
15 (6.7) 10 (0.0) 14 (7.1)
Raised LTs/liver insufficiency
(anti-diabetic drugs/antibiotics/statins)
15 (53.3) 7 (85.7) 10 (60.0)
Anemiac (omission of iron supplements) 15 (40.0) 4 (25.0) 13 (38.5)
Raised INR (coumarines) 14 (0.0) 9 (0.0) 14 (0.0)
Skin reactions (intra-venous antibiotics) 10 (0.0) 0 (0.0) 10 (0.0)
Nausea and vomiting (antibiotics) 9 (44.4) 3 (33.3) 7 (28.6)
RAAS, Renin–angiotensin–aldosterone system; NSAIDs, non-steroidal anti-inflammatory drugs; LTs, liver transaminases; INR, International
Normalization Ratio
aMainly delirium (7 ADEs), extrapyramidal symptoms (4 ADEs), falls (4 ADEs), and somnolence/drowsiness (3 ADEs)
b Delayed recovery from or sustained infections were primarily caused by inappropriate empirical antibiotic therapy choice, too short treatment
regimes, or inappropriate route of antibiotic administration (oral where intravenous was indicated)
cMainly cases of older patients with chronic cardiovascular disease who were hospitalized due to (excessive) blood loss, in whom anemia was not
sufficiently corrected to decrease risks involved with low hemoglobin values
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combination is complementary [39]. These combined aspects
of our methodology may have resulted in a higher number of
ADEs being identified. In addition, we included patients with
five or more medications on the day of admission. It is well
acknowledged that a higher number of medications signifi-
cantly increases the risk of an ADE [40]. The distribution of
ADEs in our study per severity category, however, is compa-
rable to that in other published ADE studies reporting on
severity classification [23, 41], indicating that the high ADE
yield gained in this study was, therefore, also not merely a
result of a higher identification of less clinically relevant
ADEs.
Although a direct comparison of our results on ADE
recognition in older medical inpatients with those of previ-
ous studies is not possible, some aspects of our findings can
be compared. In a study by Hohl et al. [23] conducted in an
Emergency Department (ED) setting, the medical teams did
not recognize 50 % of ADEs present upon admission in
older patients, whereas in our study this proportion was
20 %. This lower proportion can be explained by several
factors. First, the ED study of Holhl et al. [23] was con-
ducted in a Canadian hospital [23] and our study was con-
ducted in three hospitals in the Netherlands. As such, the
level of medical training in geriatrics and/or ADEs aware-
ness may differ between the physicians involved in these
two studies. Differences between healthcare settings are
known to have an impact on ADE rates [36]. Second, in
comparison to the relatively short ED visit, the time avail-
able to critically review admission medication during the
hospital stay is longer. Third, because more than 80 % of our
patients were acutely admitted, they were often first seen in
the ED. Hospital admission summaries written by ED physi-
cian’s sometimes included possible medication-related
causes promoting further examination by the treating physi-
cians on medical wards. Interestingly, the percentage of
unrecognized ADEs in our study is in line with that reported
in a study in a general inpatient population where 24 % of
ADEs were not recognized by the medical team [11]. Given
the complexity of older patients’ cases, one could expect the
proportion of unrecognized ADEs in our study to be much
higher. Unfortunately, detailed data on the type of unrecog-
nized ADEs were not presented by Nebeker et al. [11],
which hampers further exploration of this point.
Patient characteristics and ADEs recognition
The results of our multivariate analyses showed that the odds
for having an unrecognized ADE on admission decreased by
24 % with each one point increase in the Charlson Comorbid-
ity Index score [35] (95 % CI 0.59–0.97; p00.026), while
these odds appeared to be 2.4-fold higher in patients with
cognitive impairment (95 % CI 1.00–5.85; p00.05). The
former results indicate that the physicians were well aware
of the frail state of multi-morbid patients; the latter results
suggest, however, that they were insufficiently aware of
medication-related harm in patients with cognitive impair-
ment on admission. A possible explanation for the better
recognition of ADEs in multi-morbid patients is probably
the investment of more time and/or involvement of other
medical specialties. Previous studies have shown that a mul-
tidisciplinary approach is successful in improving prescribing
in older patients [42–44]. Cognitive impairment is a well-
known and highly prevalent atypical symptom in hospitalized
elderly patients [45]. Atypical disease presentation often ham-
pers correct and timely diagnosis and treatment [9]. Therefore,
such presentation may be an extra barrier in distinguishing
between disease and medications as a cause of patients’
symptoms that are present at the time of admission.
Characteristics and recognition of ADEs
In our study, recognized ADEs were more often ADEs
manifesting as new symptoms (p<0.001; df01). This find-
ing is in line with the results reported by Hohl et al. [23]
who found that ED physicians were most skillful in recog-
nizing ADEs that represented patients’ chief complaints. In
a daily practice on the wards, physicians tend to focus first
on new symptoms when making differential diagnoses. The
most plausible causes are listed, and actions prioritized
according to urgency and/or severity of the symptoms.
Worsening of existing complains, delayed recovery, or no
clinical improvement are probably more often associated
with progression of the underlying pathology or the frail
state of an older patient than with a drug effect.
As already mentioned, the task of distinguishing between
an ADE and other causes of an event in often multi-morbid,
polymedicated older inpatients is challenging [6, 9]. Our
results show that a strong causality between an event and a
drug (nearly certain or probable ADEs) improves the ability
of a physician to recognize ADEs (p00.014, df 01). The
essential distinctions between nearly certain/probable and
possible drug–event causality are that in the latter case there
may be another equally likely explanation for the event and/
or there is no information or uncertainty regarding what has
happened after the suspected medication was stopped [31].
Therefore, it is likely to assume that possible ADEs are more
easily missed. Not recognizing possible ADEs can, howev-
er, have serious consequences, as illustrated by one of our
cases—that of a 90-year-old man, recently started on mirta-
zapine 15 mg once daily for depression, presented with
dyspnoea, peripheral edema, and somnolence. The reported
incidence of somnolence with mirtazapine use is >1–10 %
and of peripheral edema >10 %. The patient was, however,
diagnosed with pneumonia, and antibiotic treatment was
initiated. The peripheral edema was treated with intravenous
furosemide boluses; treatment with mirtazapine was
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continued. One day post-discharge, the patient was readmit-
ted with increased somnolence and peripheral edema. After
consulting a geriatrician, mirtazapine was discontinued,
with subsequent resolution of the somnolence and peripher-
al edema.
In our study, CNS events, such as somnolence or deliri-
um, as well as hypotension/bradycardia, anemia, nausea/
vomiting, raised creatinine/renal insufficiency, and raised
LTs/liver insufficiency were often unrecognized as being
drug-related (>20 % unrecognized). These less well-
recognized events are examples of symptoms mimicking
the presentation of various underlying pathologies and are
less specific side-effects of medications. Moreover, in our
study, these types of ADEs represented 40 % of the most
frequently identified ADEs (Table 3) and have also been
reported as frequent events in other ADE studies in older
inpatients [5, 12–22]. It would appear that sufficient phar-
macotherapeutic and geriatric knowledge is necessary to be
able to identify these evidently more challenging ADEs [43,
44]. In the hospitals participating in this study, the day-to-
day care of inpatients is, however, provided by mostly junior
medical residents with 1 or 2 years of clinical experience.
Studies on the level of geriatric competencies of medical
residents show that there are gaps in their skills and knowl-
edge that need to be addressed to ensure that the growing
group of older inpatients receive safe care [46, 47]. In case
of ADEs resulting in raised creatinine/renal insufficiency
and raised LTs/liver insufficiency, the fact that majority of
these resulted in abnormal laboratory values only (76 %)
may additionally have attributed to the lower recognition of
these events (p00.086, df01). In the study by Hohl et al.
[23], the ER physicians were also less proficient at detecting
ADEs which resulted in abnormal laboratory values, i.e., the
so-called “silent ADEs”.
In contrast, ADEs resulting in hemorrhage, raised INR,
constipation/ileus, skin reactions, and hyper/hypoglycemia
were (almost) all recognized as being drug-related. These
ADEs are examples of events with clinically apparent con-
sequences and are very common and specific side-effects of
medications. For example, the INR is often closely moni-
tored during the hospital stay in patients taking coumarines.
According to CTCAEv3 criteria [32], a severely raised INR
implies an INR twofold the upper limit of normal (ULN) (9/
14 cases of raised INR in our study). For atrial fibrillation,
the INR target range is 2.5 to 3.5, and twofold the ULN
indicates an INR of >7.0. This clinically relevant rise, a
known effect and side-effect of coumarines, was, there-
fore, easily noticed (100 % recognized). The fact that
the majority of these well-recognized ADEs caused se-
vere or worse patient harm (57–100 %) may also have
contributed to better recognition. The unrecognized ADEs
seem more likely to be ADEs of mild or moderate severity
(p00.171, df 01).
Last but not least, in our study the majority of ADEs
(70 %) occurring during the hospital stay were caused by
medication errors. Prescribing contra-indicated medications,
dosing errors, and drug omissions accounted for 70 % of all
errors identified. Moreover, unrecognized ADEs were sig-
nificantly more often preventable ADEs (p<0.001). Many
medications used by older patients are lifelong treatments,
often prescribed (previously) by other medical specialists or
general practitioners for known therapy needs and condi-
tions at that time [6]. However, these conditions and needs
can change, and medication once chosen could become
inappropriate [6]. Physicians’ reluctance to change or ques-
tion drug therapies prescribed by colleagues is a well-known
phenomenon [48] and a possible reason why (home) med-
ication, even with errors, was continued unjustifiably.
Limitations
Our study has a number of limitations. First, methods based
on expert opinion in the identification of ADEs are known
to have a low agreement between the experts involved [49].
Given the obvious differences in knowledge and expertise
between pharmacists and physicians, such a disagreement
is, however, expected [50]. Yet, exactly because of these
differences, pharmacists and physicians are complementary
experts in terms of ADE identification [39]. Differences
between our two experts regarding their judgments on
ADE causality, severity, preventability, and recognition
were resolved by consensus. Moreover, the identification
and assessment of ADEs by our expert team were reproduc-
ible. Second, because we identified ADEs based on a retro-
spective patient chart review, a registration bias may have
occurred. Although a prospective ADE identification meth-
od has been shown, especially for preventable ADEs, to
provide more veracious results [51], an unresolved dilemma
remains because the prospective method can also bias
results given physicians’ awareness of data collection. To
use the data presented in this manuscript for an evaluation of
future interventions, we determined that a retrospective
method was more suitable to our needs. Third, a patient
chart review method is especially useful to identify prevent-
able ADEs due to prescribing errors and less helpful to
identify preventable ADEs due to administration errors
[52]. This may explain why administration errors accounted
for only 6 % of the preventable ADEs identified in this
study. We were, however, mainly interested in the subopti-
mal care from the medical perspective and less from the
nursing perspective. Although administration errors are fre-
quent, the majority of these errors do not lead to ADEs [3].
Finally, the measurement of quality of care based on chart
reviews is prone for documentation bias [53]. Actions taken
and considerations regarding the choice of therapy may not
be evident from what was recorded in patient charts and
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could, therefore, be considered inappropriate. However, it is
also well-known that actions documented in patients files
are not always performed [53]. Therefore, we collected
among other things medical files, nursing files, medication
charts, medical correspondence, laboratory and diagnostic
findings, discharge letters, and home and discharge medica-
tion lists. Our experts considered all of these different types
of sources during the structured assessment of the ADEs.
Consequently, we are confident that our chart review pro-
vides veracious results for both ADEs rates and their recog-
nition by medical teams [54].
Unanswered questions
Medication errors often have a complex causality and arise
not only from active errors, such as insufficient knowledge,
but also from factors such as a lack of training in prescribing
or insufficient supervisor’s feedback on prescribing [55].
The opportunity to investigate these so-called error provok-
ing and latent conditions was limited because we identified
ADEs by a retrospective patient chart review. By involving
the Internal Medicine staff and residents in a risk-analysis to
design future interventions, we hope to gain more insight
into these factors [56].
Future research
Our data were obtained in three different hospitals, which
increases the generalizability of our results. However, be-
cause the degree of ADEs recognition may differ between
medical specialties or countries [11, 23], more studies are
needed to confirm our findings. Strategies such as the
Screening Tool of Older Persons’ potentially inappropriate
Prescriptions (STOPP), Screening Tool to Alert doctors to
the Right Treatment (STOP) [57], and quality indicators for
in-hospital pharmaceutical care of elderly patients [58] have
the potential to improve the recognition of ADEs by detect-
ing inappropriate prescribing. Considering ADEs as a dif-
ferential diagnosis in older patients should be a standard
approach on admission and during the hospital stay. Medical
education regarding ADEs, a regular and comprehensive
medication review [6, 10, 59], a daily participation of clin-
ical pharmacists in medical teams on the wards [60–62], and
CDSSs [63, 64] specific to older inpatients’medication risks
[65, 66] could all be of an added value in reducing prevent-
able ADEs and improving ADE recognition.
Conclusions
By applying a comprehensive measurement strategy that
included the identification of ADEs present upon admission
and those occurring during the hospital stay, followed by an
assessment of medical teams’ ability to recognize these
ADEs, we were able to identify patient- and ADE-related
factors influencing the ability of medical teams to recognize
ADEs in older vulnerable patients. The medical teams in-
volved performed best at recognizing ADEs manifesting as
new or clinically apparent symptoms and those causing
serious patient harm. Less specific ADEs mimicking under-
lying pathology, ADEs with only an abnormal laboratory
value or mild to moderately severe ADEs were less well
recognized. However, physicians should also aim at achiev-
ing timely recognition of such less critical and less evident
ADEs to prevent future emergencies. The findings of this
study suggest areas where physicians should focus their
attention in order to further improve their ability to recog-
nize ADEs.
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